Volume 62, Issue 1, Pages (July 2002)

Slides:



Advertisements
Similar presentations
Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.
Advertisements

Kamyar Kalantar-Zadeh  Kidney International 
Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports  Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Pleiotropic effects of the non-calcium phosphate binder sevelamer
Volume 56, Pages S238-S241 (July 1999)
New tools in diagnosing renal artery stenosis
Steven Fishbane, Jeffrey S. Berns, M.D.  Kidney International 
Fig. 1. (A) Non-contrast CT (calcium score scan) showing no calcification in the right coronary artery (arrow). (B) First-phase contrast-enhanced CT showing.
K. Kiryluk, F. Khan, A. Valeri  Kidney International 
Volume 75, Issue 1, Pages 7-9 (January 2009)
Anemia management in chronic kidney disease
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients  G.A. Block, P. Raggi, A. Bellasi, L. Kooienga,
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
New tools in diagnosing renal artery stenosis
Manjula Kurella, Jennifer Luan, Kristine Yaffe, Glenn M. Chertow 
Volume 68, Issue 4, Pages (October 2005)
Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real?  S. Andrulli, S. Di Filippo, F. Locatelli 
Association of Thoracic Aorta Calcium Score With Left Ventricular Hypertrophy and Clinical Outcomes in Patients With Severe Aortic Stenosis After Aortic.
Kamyar Kalantar-Zadeh  Kidney International 
Jeffrey C. Fink, Glenn M. Chertow  Kidney International 
The Case ∣ An unusual cause of renovascular hypertension
Aortic Calcification Increases the Risk of Anastomotic Leakage After Ivor-Lewis Esophagectomy  Lucas Goense, MD, Peter S.N. van Rossum, MD, Teus J. Weijs,
Coronary artery disease in uremia: Etiology, diagnosis, and therapy
Kiran Devisetty, MD, Joseph K. Salama, MD  Journal of Thoracic Oncology 
Estimation of podocyte number: A comparison of methods
Volume 4, Issue 2, (February 2007)
A new era in phosphate binder therapy: What are the options?
Pleiotropic effects of the non-calcium phosphate binder sevelamer
Aortic stent-grafting facilitates a successful resection after neoadjuvant treatment of a cT4 esophageal cancer  Tomoki Makino, MD, Takushi Yasuda, MD,
N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment  Martina Franz, Wolfgang Woloszczuk, Walter.
(A) Sagittal section through the thoracic aorta demonstrating division of the ascending aorta from the sinotubular junction to the origin of the left subclavian.
Volume 77, Issue 7, Pages (April 2010)
Volume 87, Issue 2, Pages (February 2015)
Blood pressure targets in hemodialysis patients
Volume 61, Issue 4, Pages (April 2002)
Volume 69, Issue 10, Pages (May 2006)
Volume 67, Issue 1, Pages (January 2005)
Cardiovascular complications in chronic kidney disease
Progression of polycystic kidney disease in a kidney transplant
Role of vitamin D receptor activators on cardiovascular risk
A physician's perseverance uncovers problems in a key nephrology study
Cardiac arrest and sudden death in dialysis units
Effects of hemodialysis on cardiac function
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 64, Issue 1, Pages (July 2003)
Calcium on trial: Beyond a reasonable doubt?
Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival.
Tuberculous autonephrectomy
Unilateral renal cystic disease
Cardiovascular calcification in patients with chronic renal failure: Are we on target with this risk factor?  Peter A. Mccullough, Sandeep Soman  Kidney.
Hemoglobin variability in epoetin-treated hemodialysis patients
M. Rivera, G. Tabernero, C. Galeano, J.L. Teruel, J. Ortuño 
Daily nocturnal home hemodialysis
Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia  Markus Ketteler, Christoph.
Volume 66, Issue 5, Pages (November 2004)
Atherosclerotic nephropathy
Volume 56, Pages S238-S241 (July 1999)
Volume 80, Issue 10, Pages (November 2011)
Hydronephrosis caused by fecal impaction
Volume 70, Issue 9, Pages (November 2006)
Volume 74, Issue 9, Pages (November 2008)
Delayed presentation of traumatic aortocaval fistula: A report of two cases and a review of the associated compensatory hemodynamic and structural changes 
Volume 70, Issue 5, Pages (September 2006)
Vasopressin antagonists in polycystic kidney disease
Mary B. Leonard, Lynn A. Donaldson, Martin Ho, Denis F. Geary 
Volume 72, Issue 12, (December 2007)
Change in bone in patients who were treated with calcium or sevelamer.
Change in coronary artery calcification in patients who were treated with calcium or sevelamer. Change in coronary artery calcification in patients who.
Presentation transcript:

Volume 62, Issue 1, Pages 245-252 (July 2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients  Glenn M. Chertow, Steven K. Burke, Paolo Raggi, for the Treat to Goal Working Group  Kidney International  Volume 62, Issue 1, Pages 245-252 (July 2002) DOI: 10.1046/j.1523-1755.2002.00434.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 (A) Median percentage change in coronary artery calcification scores from baseline to week 26 and week 52 in patients with calcification (scores ≥30) at baseline.*Indicates within-treatment, P < 0.001. Comparisons between calcium-treated (■) and sevelamer-treated (▪) groups, P = 0.01 at week 26 and P = 0.02 at week 52. Corresponding values for volume score were 9% versus 18% (P = 0.02) for sevelamer and calcium at week 26, respectively, and 10% versus 28% (P = 0.04) for sevelamer and calcium at week 52, respectively. (B) Median percentage change in aortic calcification scores from baseline to week 26 and week 52 in patients with calcification (scores ≥30) at baseline. *Indicates within treatment, P < 0.001. Comparisons between calcium- and sevelamer-treated groups, P = 0.01 at week 26 and P = 0.02 at week 52. Corresponding values for volume score were 10% versus 23% (P = 0.02) for sevelamer and calcium at week 26, respectively, and 22% versus 37% (P = 0.05) for sevelamer and calcium at week 52, respectively. Kidney International 2002 62, 245-252DOI: (10.1046/j.1523-1755.2002.00434.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Comparison of axial electron beam tomography (EBT) sections of the heart of a patient treated with sevelamer. The 52-week scan (right panel) shows a smaller total coronary artery calcium score than the initial scan (left panel). The computer software automatically assigns a color code to each plaque based on its density with a transition from various shades of red to blue as density increases. In this case the delayed scan demonstrates a less dense plaque in the middle of the right coronary artery (white arrows). Kidney International 2002 62, 245-252DOI: (10.1046/j.1523-1755.2002.00434.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 (A) Nominal change in coronary artery coronary artery volume scores from baseline to week 52 by baseline calcification group. (B) Nominal change in aorta volume scores from baseline to week 52 by baseline calcification group. Symbols are: (▪) sevelamer; (■) calcium. Kidney International 2002 62, 245-252DOI: (10.1046/j.1523-1755.2002.00434.x) Copyright © 2002 International Society of Nephrology Terms and Conditions